Last reviewed · How we verify

Kefadol (CEFAMANDOLE NAFATE)

Eli Lilly · FDA-approved approved Small molecule

Kefadol (generic name: CEFAMANDOLE NAFATE) is a cefamandole nafate Small molecule drug developed by Eli Lilly. It is currently FDA-approved (first approved 1978).

Kefadol works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Kefadol, also known as cefamandole nafate, is a small molecule antibiotic in the cefamandole class. Originally developed by Lilly and currently owned by the same company, it was FDA approved in 1978. Although its target and exact mechanism of action are unknown, it is used to treat various bacterial infections. Kefadol is now off-patent and available as a generic medication. As with any antibiotic, it is essential to use Kefadol judiciously to prevent the development of antibiotic-resistant bacteria.

At a glance

Generic nameCEFAMANDOLE NAFATE
SponsorEli Lilly
Drug classcefamandole nafate
TargetBacterial penicillin-binding protein
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved
First approval1978

Mechanism of action

Imagine the bacterial cell wall as a strong, protective shield. Kefadol disrupts the process of building this shield, causing the bacteria to weaken and eventually die. This allows the body's immune system to fight off the infection more effectively.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Kefadol

What is Kefadol?

Kefadol (CEFAMANDOLE NAFATE) is a cefamandole nafate drug developed by Eli Lilly.

How does Kefadol work?

Kefadol works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Who makes Kefadol?

Kefadol is developed and marketed by Eli Lilly (see full Eli Lilly pipeline at /company/eli-lilly).

What is the generic name of Kefadol?

CEFAMANDOLE NAFATE is the generic (nonproprietary) name of Kefadol.

What drug class is Kefadol in?

Kefadol belongs to the cefamandole nafate class. See all cefamandole nafate drugs at /class/cefamandole-nafate.

When was Kefadol approved?

Kefadol was first approved on 1978.

What development phase is Kefadol in?

Kefadol is FDA-approved (marketed).

What does Kefadol target?

Kefadol targets Bacterial penicillin-binding protein and is a cefamandole nafate.

Related